5-氯吡啶-2-甲基甲磺酸甲酯 | 864758-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氯吡啶-2-甲基甲磺酸甲酯
• 英文名称: (5-chloro-2-pyridinyl)methyl methanesulfonate
• 英文别名: (5-chloropyridin-2-yl)methyl methanesulfonate；5-chloro-2-methanesulfonyloxymethylpyridine
• CAS: 864758-02-1
• 化学式: C₇H₈ClNO₃S
• 分子量: 221.664
• InChiKey: WTCGXRIUCCNDOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-氯吡啶-2-甲基甲磺酸甲酯 、 4-hydroxy-1-{4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]phenyl}pyridin-2(1H)-one 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以79%的产率得到4-[(5-chloropyridin-2-yl)methoxy]-1-{4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]phenyl}pyridin-2(1H)-one
  参考文献：
  名称：

  PHENYLPYRIDONE DERIVATIVE

  摘要：

  公开号：

  EP1921065B1
• 作为产物：
  描述：

  (5-氯-2-吡啶基)甲醇 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 5-氯吡啶-2-甲基甲磺酸甲酯
  参考文献：
  名称：

  [EN] N- SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE - GATED SODIUM CHANNELS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  公开号：

  WO2012007869A3

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS
  申请人：ORION CORPORATION

  公开号：US20160368906A1

  公开（公告）日：2016-12-22

  The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Cy 1 , Cy 2 , X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.

  本公开提供了公式（I）的双环杂环衍生物，可能在治疗上有用，更具体地作为溴结构域抑制剂；（I）中，R1、R2、R3、R4、L1、L2、Cy1、Cy2、X、n和虚线具有规范中给定的相同含义，以及其在治疗和预防疾病或疾病中有用，特别是在与溴结构域抑制剂相关的疾病或疾病中的使用。本公开还提供了制备化合物和包括至少一种公式（I）的双环杂环衍生物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• Bicyclic aromatic substituted pyridone derivative
  申请人：Sakuraba Shunji

  公开号：US20090264426A1

  公开（公告）日：2009-10-22

  Disclosed is a compound represented by the formula (I): Wherein R 1 and R 2 independently represent a hydrogen atom, a lower alkyl group or the like; X 1 , X 2 and X 3 independently represent a methine group or a nitrogen atom; Y 1 and Y 3 independently represent a single bond, —O— or the like; Y 2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z 1 and Z 2 independently represent a single bond, a C 1-4 alkylene group or the like; Ar 1 represents an aromatic carbocyclic ring or the like; and Ar 2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.

  本发明揭示了一种化合物，其化学式为（I）：其中R1和R2分别代表氢原子、低碳烷基或类似物；X1、X2和X3分别代表亚甲基基团或氮原子；Y1和Y3分别代表单键、—O—或类似物；Y2代表低碳烷基基团或类似物；W1至W4独立地代表单键、亚甲基基团或类似物；L代表单键、亚甲基基团或类似物；Z1和Z2独立地代表单键、C1-4烷基基团或类似物；Ar1代表芳香环烷基环或类似物；Ar2代表双环芳香环烷基环或类似物。该化合物可用作治疗中枢疾病、心血管疾病或代谢性疾病的药物。
• Pyridone derivative
  申请人：Otake Norikazu

  公开号：US20070208046A1

  公开（公告）日：2007-09-06

  The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R 1 and R 2 may be same or different and stands for H, etc., or R 1 and R 2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X 1 -X 3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X 4 -X 7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y 1 and Y 3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y 2 stands for lower alkylene, etc.; R stands for H, etc., L stands for methylene; Z 1 and Z 2 may be same or different and stand for single bond or lower alkylene; or R 1 , L and Z 2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R 1 binds; and Ar stands for aromatic carbocyclic group, etc.].

  该发明提供了由通式（I）表示的吡啶酮衍生物[在公式中，R1和R2可能相同或不同，代表H等，或者R1和R2可能与它们结合的N一起形成一个脂肪族含氮杂环基团；X1-X3可能相同或不同，代表亚甲或N，但不能同时都代表氮；X4-X7可能相同或不同，代表亚甲或N，但不能同时有三个或更多同时代表N；Y1和Y3可能相同或不同，代表单键，-O-，-NR-，-S-等；Y2代表较低的烷基等；R代表H等，L代表亚甲基；Z1和Z2可能相同或不同，代表单键或较低的烷基；或者R1、L和Z2可能与R1结合的N一起形成一个脂肪族含氮杂环基团；Ar代表芳香族碳环基团等]。
• Phenylpyridone Derivative
  申请人：Naya Akira

  公开号：US20090137587A1

  公开（公告）日：2009-05-28

  A compound represented by the formula (I) is contained as an active ingredient: wherein R 1 and R 2 independently represent a hydrogen atom, a lower alkyl group or the like, or R 1 together with a nitrogen atom to which L, Z 2 and R 1 are attached may form an aliphatic nitrogenated heterocyclic group and R 1 and R 2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH 2 —O—, —CH═CH— or the like; Z 1 represents a single bond, a C 1-4 alkylene group or the like; Z 2 represents a single bond or a C 1-4 alkylene group; L represents a methylene group, a C 3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.

  化合物的化学式为（I），其中包含作为活性成分的化合物：其中R1和R2独立地表示氢原子，低碳基团或类似物，或者R1与L，Z2和R1附着的氮原子一起可以形成脂肪族氮杂环基团，R1和R2与它们附着的氮原子一起可以形成脂肪族氮杂环基团；X表示亚甲基基团或氮原子；Y表示-CH2-O-，-CH═CH-或类似物；Z1表示单键，C1-4烷基撇或类似物；Z2表示单键或C1-4烷基撇；L表示亚甲基基团，C3-8环烷基撇或类似物；Ar表示芳香族碳环基团或类似物。该化合物可用作中枢神经系统疾病、心血管疾病或代谢性疾病的药物。
• PYRIDONE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1741703A1

  公开（公告）日：2007-01-10

  The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R1 and R2 may be same or different and stands for H, etc., or R1 and R2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X1-X3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X4-X7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y1 and Y3 may be same or different and stand for single bond, -0-, -NR-, -S-, etc ; Y2 stands for lower lkylene, etc.; R stands for H, etc., L stands for methylene; Z1 and Z2 may be same or different and stand for single bond or lower alkylene; or R1, L and Z2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R1 binds; and Ar stands for aromatic carbocyclic group, etc.].

  本发明提供了通式 (I) 所代表的吡啶酮衍生物 [式中，R1 和 R2 可以相同或不同，代表 H 等、或 R1 和 R2 可与它们结合的 N 一起形成一个脂族含氮杂环基团；X1-X3 可相同或不同，代表甲烷或 N，条件是它们中的三个或更多不同时代表氮；X4-X7 可相同或不同，代表甲烷或 N，条件是它们中的三个或更多不同时代表 N；Y1 和 Y3 可相同或不同，代表单键、-0-、-NR-、-S-等；Y2 代表低级亚烷基等。R 代表 H 等、L 代表亚甲基；Z1 和 Z2 可相同或不同，代表单键或低级亚烷基；或 R1、L 和 Z2 可与 R1 结合的 N 形成脂肪族含氮杂环基团；Ar 代表芳香族碳环基团等]。